1. Home
  2. CLOV vs HROW Comparison

CLOV vs HROW Comparison

Compare CLOV & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clover Health Investments Corp.

CLOV

Clover Health Investments Corp.

HOLD

Current Price

$4.59

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

HROW

Harrow Inc.

HOLD

Current Price

$40.63

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLOV
HROW
Founded
2014
1998
Country
United States
United States
Employees
N/A
373
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CLOV
HROW
Price
$4.59
$40.63
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$2.90
$69.86
AVG Volume (30 Days)
4.5M
473.3K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
38.03
N/A
EPS
0.10
N/A
Revenue
$1,924,308,000.00
N/A
Revenue This Year
$52.59
$31.62
Revenue Next Year
$15.37
$50.77
P/E Ratio
$94.65
N/A
Revenue Growth
40.34
N/A
52 Week Low
$1.58
$28.54
52 Week High
$5.59
$54.98

Technical Indicators

Market Signals
Indicator
CLOV
HROW
Relative Strength Index (RSI) 52.78 48.54
Support Level $4.12 $37.03
Resistance Level $4.88 $41.82
Average True Range (ATR) 0.25 1.74
MACD 0.02 -0.12
Stochastic Oscillator 45.79 50.16

Price Performance

Historical Comparison
CLOV
HROW

About CLOV Clover Health Investments Corp.

Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: